Tenecteplase in Acute Ischemic Stroke
Tenecteplase is a modified tissue plasminogen activator (tPA) administered as a single 0.25 mg/kg IV bolus for acute ischemic stroke, offering a practical alternative to alteplase with similar safety and efficacy, particularly advantageous in patients with minor neurological impairment and no major intracranial occlusion. 1
What is Tenecteplase?
Tenecteplase is a genetically engineered variant of alteplase (standard tPA) with specific molecular modifications that provide superior pharmacological properties 2:
- Longer half-life (90-130 minutes) allowing single bolus administration
- Higher fibrin specificity enabling more targeted clot dissolution with less systemic plasminogen activation
- Greater resistance to plasminogen activator inhibitor-1
- Modified structure: 527-amino acid glycoprotein with substitutions at threonine 103, asparagine 117, and a tetra-alanine substitution at amino acids 296-299
These modifications translate into practical clinical advantages: easier administration, potentially faster reperfusion, and reduced systemic bleeding compared to the standard 1-hour alteplase infusion 3, 4.
How is it Used During Acute Ischemic Stroke?
Dosing and Administration
Administer 0.25 mg/kg as a single IV bolus (not to exceed maximum dose based on weight) 1, 5. This is given as a single push over 5-10 seconds, in stark contrast to alteplase's bolus plus 1-hour infusion 1.
Patient Selection Based on 2018 AHA/ASA Guidelines
The 2018 AHA/ASA guidelines provide a Class IIb recommendation (may be considered) for tenecteplase in specific populations 1:
Ideal candidates:
- Minor neurological impairment (median NIHSS score ~4 in trials)
- No major intracranial occlusion on vascular imaging
- Within 4.5 hours of symptom onset (standard window)
- Otherwise eligible for IV thrombolysis
Important caveat: The guidelines note that tenecteplase "has not been proven to be superior or noninferior to alteplase" based on the largest trial of 1100 subjects at 0.4 mg/kg, which failed to demonstrate superiority 1. However, the 0.25 mg/kg dose has shown particular promise in phase 2 trials for large vessel occlusions.
Time Window Considerations
- Standard window: Within 4.5 hours of symptom onset or last known well 6
- Extended window: Trials have investigated use up to 6 hours, with emerging evidence for extended windows up to 24 hours when advanced imaging demonstrates salvageable tissue 1, 7
- Wake-up stroke: Can be considered with MRI showing DWI-FLAIR mismatch, similar to alteplase protocols 6
Integration with Mechanical Thrombectomy
Critical practice point: Do NOT wait to assess clinical response to tenecteplase before proceeding to mechanical thrombectomy 1. The 2018 guidelines explicitly state this as Class III: Harm recommendation. Patients eligible for both should receive tenecteplase immediately and proceed directly to catheter angiography without delay 1, 6.
This "bridging therapy" approach is supported by evidence showing tenecteplase may enhance recanalization rates before thrombectomy, particularly in large vessel occlusions 8.
Evidence Synthesis and Clinical Context
Recent High-Quality Evidence
The 2024 ORIGINAL trial (1465 patients) demonstrated noninferiority of tenecteplase 0.25 mg/kg to alteplase 9:
- Primary outcome (mRS 0-1 at 90 days): 72.7% vs 70.3% (RR 1.03,95% CI 0.97-1.09)
- Symptomatic ICH: 1.2% in both groups
- 90-day mortality: 4.6% vs 5.8%
This represents the most recent and highest quality evidence supporting tenecteplase as a suitable alternative.
Real-World Safety Data
A 2026 large telestroke network study (1526 patients, 1389 receiving tenecteplase) showed no significant differences in favorable outcomes, symptomatic ICH, or mortality compared to alteplase in routine practice 10. This real-world evidence supports the safety and effectiveness of widespread tenecteplase adoption.
Practical Advantages
Why tenecteplase is gaining widespread adoption 3, 4, 8:
- Single bolus administration reduces medication errors
- Faster treatment initiation in emergency settings
- Shorter door-to-needle times
- Easier for paramedic administration in pre-hospital settings
- Lower cost in many healthcare systems
- Simplified workflow in emergency departments
Limitations and Ongoing Questions
Important nuances from the guidelines 1:
- The 0.4 mg/kg dose showed no advantage over 0.25 mg/kg
- Evidence is strongest for patients with minor deficits and no large vessel occlusion
- Superiority over alteplase remains unproven in general stroke populations
- Most benefit may be in large vessel occlusion subgroups (based on phase 2 data showing superior recanalization)
Common Pitfalls to Avoid
Do not use doses other than 0.25 mg/kg for stroke (the 0.4-0.5 mg/kg dose used for MI is not appropriate) 1, 5
Do not delay mechanical thrombectomy to assess tenecteplase response—this causes harm 1
Do not assume superiority—current evidence supports noninferiority and "might be considered as an alternative," not replacement in all cases 1
Apply same contraindications as alteplase—blood pressure must be <185/110 mmHg before administration 6
Do not use other fibrinolytics (streptokinase, desmoteplase) outside clinical trials—these have shown no benefit or harm 1
Current Clinical Practice
Tenecteplase is increasingly used as a first-line thrombolytic in many stroke centers globally, with regulatory approval granted in Western countries as of 2024 and expected in major Asian countries by 2025-2026 11. The 2018 AHA/ASA guidelines position it as a second-tier option, but more recent evidence and practical considerations have driven broader adoption 5, 12, 7.
For patients with large vessel occlusion proceeding to thrombectomy, tenecteplase at 0.25 mg/kg is particularly attractive due to ease of administration and potential for enhanced recanalization before endovascular intervention 8, 11.